Search Results
May 18, 2026, 07:00 ET Earendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)
atopic dermatitis, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease." Zhenping Zhu, MD, PhD, President & Co-CEO of Earendil Labs, commented, "HXN-1011 represents a highly differentiated next-generation TSLP antagonist with the best-in-class
More news about: Earendil Labs
May 17, 2026, 21:13 ET El Día de la Innovación de ACROBiosystems llega a Zúrich
participación de ponentes destacados: Jenny Ann Prange, PhD, jefa de Gestión de Proyectos en Wyss Zurich, Plataforma de Tecnologías de Medicina Regenerativa, Universidad de Zúrich; Lili Qin, PhD, vicepresidenta de I+D en ACROBiosystems; Chiara F Magnani, PhD, profesora adjunta en el Hospital Universitario de
More news about: ACROBiosystems Group
May 17, 2026, 21:12 ET ACROBiosystems Innovation Day in Zürich bringt führende Köpfe zur Erkundung neuer Biotech-Grenzen zusammen
Referentinnen und Referenten gehörten Jenny Ann Prange, PhD, Head of Project Management der Regenerative Medicine Technologies Platform von Wyss Zurich an der Universität Zürich; Lili Qin, PhD, Vice President of R&D bei ACROBiosystems; Prof. Chiara F. Magnani, PhD, Assistant Professor am Universitätsspital Zürich
More news about: ACROBiosystems Group
May 17, 2026, 21:10 ET Zurich accueille la journée de l'innovation d'ACROBiosystems : les plus grands esprits s'unissent pour explorer les frontières de la biotechnologie
rassemblé d'éminents orateurs : Jenny Ann Prange, PhD, responsable de la gestion de projet à Wyss Zurich, Regenerative Medicine Technologies Platform, Université de Zurich ; Lili Qin, PhD, vice-présidente de la R&D chez ACROBiosystems ; Chiara F Magnani, PhD, professeure assistante à l'Hôpital universitaire
More news about: ACROBiosystems Group
May 15, 2026, 16:05 ET Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer
Health and Accuray will build on this shared history to advance the next generation of adaptive radiotherapy approaches, according to Zachary Morris, MD, PhD, professor and chair of human oncology. "At UW we have exceptionally talented innovators in radiation medicine across the spectrum from discovery science
More news about: Accuray Incorporated
May 15, 2026, 14:00 ET PHARMACISTS MUTUAL ANNOUNCES BOARD TRANSITIONS, HONORS RETIRING DIRECTORS AND WELCOMES NEW MEMBERS
transition, Pharmacists Mutual also announces the election of three new directors: Troy Trygstad, Jack Young, and Scott Pace.Troy Trygstad (PharmD, PhD, MBA) is Executive Director of CPESN USA, a national clinically integrated network of more than 3,500 community pharmacies. He brings extensive experience
More news about: Pharmacists Mutual Insurance Group
May 15, 2026, 08:00 ET Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will participate in a virtual fireside chat as part of the 2026 Stifel Virtual Targeted Oncology Forum on Tuesday, May 19, 2026,
More news about: Whitehawk Therapeutics, Inc.
May 15, 2026, 08:00 ET ARKEUS ANNOUNCES $18M SERIES A TO SCALE AI SENSING SYSTEMS FOR AUTONOMOUS PLATFORMS OPERATING IN CONTESTED MILITARY ENVIRONMENTS
Dr Nebauer is an aerospace engineer and optical sensing specialist with deep expertise in autonomous software and hardware systems. He holds a PhD in Aerospace Engineering focused on spectral-method solutions, alongside degrees in Aerospace Engineering and Physics with a concentration in High Performance
More news about: Arkeus
May 15, 2026, 06:30 ET Starget Pharma, caVos Biotherapeutics, Protai and BAIBYS™ Awarded Most Innovative Life Science Startups at Biomed Israel 2026
Naschitz, 9vc; Reut Shema, PhD, aMoon; Neta-li Feuerstein Ganor, Eli Lilly; Adar Makovski Silverstein, PhD, Arkin Bio Ventures; Yael Gruenbaum-Cohen, PhD, Entree Bio Ventures; Irit Yaniv, MD, Almeda; Joseph Korff, ARC Ventures; Yair Benita, PhD, AION labs; Peter Kash, PhD, Camelot BioCapital
More news about: Biomed Israel
May 14, 2026, 16:13 ET American Society of Gene and Cell Therapy Awards Beverly L. Davidson, PhD, Outstanding Achievement Award
Beverly L. Davidson, PhD, Director of the
More news about: Children's Hospital of Philadelphia
May 14, 2026, 13:50 ET VTEM Airborne Survey is Underway on VR's Empire Copper-Nickel-PGM Project in Ontario
this document, and on the Company's website, has been reviewed and approved on behalf of the Company by the President & CEO, Dr. Michael Gunning, PhD, P.Geo., a non-independent Qualified Person.ABOUT VR RESOURCES LTD.VR is an established junior exploration company based in Vancouver.
More news about: VR Resources Limited
May 14, 2026, 12:57 ET Hidden small RNA determines if cholera bacterium can infect humans
Salvador Almagro-Moreno, PhD, St. Jude
More news about: St. Jude Children's Research Hospital
May 14, 2026, 12:00 ET Ksana Health Awarded ARPA-H Contract to Build a Behavioral Health Foundation Model
$4.9 trillion in annual health expenditures, yet we still rely on fragmented, episodic approaches to detection and intervention," said Nick Allen, PhD, CEO of Ksana Health and Principal Investigator on the project. "This project will harness the sensing capabilities of people's personal smartphones
More news about: Ksana Health
May 14, 2026, 09:40 ET Enlil Caps Record Q1 2026 with Eight New MedTech Customers
lean, fast-moving MedTech company. Enlil delivered on both, and we were implemented faster than we thought possible," said Dr. Rafael Veraza, PhD, MPH, CEO of Vascular Perfusion Solutions."We are in a great spot. Our rollout of the quality system is complete, and the team is trained.
More news about: Enlil, Inc.
May 14, 2026, 09:04 ET InsideTracker Unveils New AI Platform Empowering Wellness Brands to Deliver Hyper-Personalized Health Guidance at Scale
Renée Deehan, PhD, SVP of Science and AI at InsideTracker, "We're giving businesses a low-lift, fast-to-market way to meet demand for health guidance that's precisely
More news about: InsideTracker
May 14, 2026, 09:03 ET SONOMOTION BREAK WAVE™ LITHOTRIPSY DEVICE MEETS PIVOTAL TRIAL PRIMARY ENDPOINTS
compact device puts us in a strong position to bring Break Wave to the millions of patients who suffer from kidney stones each year," said Oren Levy, PhD, Co-Founder and Chief Executive Officer of SonoMotion. "We are proud of the team for continuously improving the technology, and are delighted to offer
More news about: SonoMotion, Inc.
May 14, 2026, 09:00 ET Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
therapeutic activity. We look forward to evaluating GTB-5550 across multiple solid tumor types as we continue dose escalation.", said Dr. Nicholas Zorko, MD, PhD, Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation, The University of Minnesota.GTB-5550 will be administered
More news about: Market News Updates
May 14, 2026, 08:38 ET Ampa Accelerates Rollout of Portable Neuromodulation Platform for Depression with Oversubscribed Financing
has historically been too expensive, large, and complex for most clinics to offer. Ampa, co-founded by seminal researcher Jonathan Downar, MD, PhD, has developed a new TMS device that costs $3,000 per month, fits in the trunk of a car, and can be operated after a few hours of training.Today, Ampa
More news about: Ampa
May 14, 2026, 08:30 ET Butterfly Medical Secures $21 Million in Upsized Series C Funding to Advance Minimally Invasive BPH Treatment
development efforts, which have achieved a stage similar to other minimally invasive BPH solutions with less than half the capital," said Nayan Parekh, PhD, Managing Partner at New Rhein Healthcare Investors and Chairman of the Board at Butterfly Medical. "Based on the platform's clinical data, ease of use,
More news about: Butterfly Medical
May 14, 2026, 08:10 ET CREATE Medicines Strengthens Clinical and Scientific Advisory Board with Appointment of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD
Wiesendanger, MD, PhD Christopher Jewell, PhDRon Vale, PhDCameron Turtle, MBBS, PhDSiddhartha Mukherjee, MD, DPhilAlberto Mantovani, MDMichael Dee Gunn, MDNicholas King, MBChB, PhDMartin Guilliams, PhDGeorg
More news about: CREATE Medicines, Inc.
May 14, 2026, 08:00 ET CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology
platformRon Philip joins as Executive Chairman; Brian Cuneo of ARCH Venture Partners and Tom Thomas, PhD, of Newpath Partners join the Board of DirectorsCAMBRIDGE, Mass.,
More news about: CREATE Medicines, Inc.
May 14, 2026, 08:00 ET KS&R introduces the ECHO Index to Bring Greater Transparency and Governance to Synthetic Data
result is an easy to interpret index for organizations to quantify confidence in any synthetic model.The initiative is led by Ben Cortese, PhD, Senior Vice President of KS&R's Decision Sciences & Innovation team, who is focused on advancing KS&R's work in synthetic data, AI governance,
More news about: KS&R
May 14, 2026, 07:00 ET GEMMABio Unveils Duchenne Muscular Dystrophy (DMD) Program and Presents Preclinical Data for Next‑Generation Gene Therapies for DMD and Spinal Muscular Atrophy Type 1 (SMA1) at the ASGCT 2026 Annual Meeting
comprehensive preclinical data for GB221, a next-generation, investigational gene therapy for spinal muscular atrophy type 1 (SMA1). Juliette Hordeaux, DVM, PhD, DECVP, Chief Scientific Officer at GEMMABio, will present the DMD data today at 8:15 a.m. ET and the SMA1 work at 3:30 p.m. ET during oral presentations
More news about: GEMMA Biotherapeutics
May 14, 2026, 06:00 ET Ring Therapeutics® Presents its Vector Conjugate and VectorBricks™ Manufacturing Platforms at the 29th Annual American Society of Gene & Cell Therapy Conference
delivers orders of magnitude more payload than antibodies and can carry anything from small molecules to oligonucleotides," said Dmitriy Bobrovnikov, PhD, Chief Innovation Officer of Ring Therapeutics. "The data we are presenting at ASGCT highlight how our vectors carry siRNA directly as Vector Oligo Conjugates
More news about: Ring Therapeutics
May 13, 2026, 23:30 ET Cool Effect Builds on Market-Leading Superpollutant Portfolio with Addition of Rice Methane Reduction Project from Mitti Labs
systems and local communities."High-quality climate solutions require both strong science and real-world applicability," said Johanna Depenthal, PhD, Director of Project Research at Cool Effect. "Mitti Labs' approach shows how innovative monitoring combined with farmer-centered implementation can
More news about: Mitti Labs